{"filings":[{"id":471559,"accession_number":"0001213900-26-057828","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-05-15T20:29:39+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.","Net loss of $3.3M ($0.05 EPS) vs $2.3M ($0.04 EPS) YoY, driven by higher other expense.","Loss from operations improved 16% to $0.8M from $1.0M, reflecting cost-cutting measures.","MENA segment sales surged 446%, partially offsetting U.S. decline.","Cash and equivalents $1.1M at March 31, 2026, down from $2.1M at December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1982000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99067,"accession_number":"0001213900-26-045250","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus appoints Henry H. Du to board; replaces resigned director Jon Kuwahara","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Henry H. Du appointed to fill board vacancy created by resignation of Jon Kuwahara; expected to become sole Audit Committee member.","Du is VP Finance & Accounting and interim CFO at Alpha Cognition (NASDAQ: ACOG); CPA with BA from Claremont McKenna.","No family relationships with other officers/directors; Du to be compensated on same basis as other directors.","Jon Kuwahara resigned from board; no reason provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99066,"accession_number":"0001213900-26-043577","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Jon Kuwahara resigns from Emmaus Life Sciences board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Jon Kuwahara resigned from the board of Emmaus Life Sciences on April 13, 2026, effective April 15, 2026.","Willis Lee remains Chairman and Chief Executive Officer of Emmaus Life Sciences.","Emmaus Life Sciences has no securities registered under Section 12(b) of the Exchange Act and no trading symbol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114870,"accession_number":"0001213900-26-036886","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).","Income from operations $0.2M, improved from operating loss of $1.9M; operating expenses fell 34% to $11.4M.","Cash and equivalents $2.1M at Dec 31, 2025, up from $1.4M at Dec 31, 2024.","Entered license/distribution deal with NeoImmuneTech for U.S. operations, expected Q2 2026.","Revenue drop driven by generic L-Glutamine competition in U.S., partially offset by MENA growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114869,"accession_number":"0001213900-26-023644","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.","Supply price is Emmaus' production cost plus a specified double-digit percentage margin.","Effective Date contingent on NIT obtaining necessary regulatory approvals and licensing; must occur by October 1, 2026.","Either party may terminate if Effective Date does not occur by Oct 1, 2026 (unless due to Emmaus' wrongful acts).","Exclusive Supply Agreement is a follow-up to the License Agreement reported on December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131264,"accession_number":"0001213900-25-126728","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Emmaus Life Sciences licenses Endari to NeoImmuneTech for US/Canada with upfront and royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Emmaus grants NeoImmuneTech (NIT) exclusive rights to market Endari for sickle cell disease in US and Canada; upfront payment plus royalty on NIT sales.","Effective date conditioned on NIT obtaining regulatory approvals; either party may terminate if not met by Oct 1, 2026.","Emmaus will supply Endari to NIT at cost-plus margin; selected US sales force to transfer to NIT pending effective date.","If NIT fails to meet annual minimum sales, the license becomes non-exclusive.","Emmaus CEO says deal allows refocus on higher-growth regions: Middle East, Brazil, Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131263,"accession_number":"0001213900-25-124513","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences exchanges $3M note for $600K note and 6.33M shares (9% dilution)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged $3M convertible note (10% interest, conversion $0.13) for $600K new note (10%, conversion $0.01 adjustable) and 6,332,692 shares valued at ~$0.38 each.","The 6.33M common shares represent 9.0% of total outstanding shares post-issuance.","New note is due on demand; conversion price adjusts quarterly based on average VWAP.","Issued under Section 3(a)(9) exemption with no additional consideration.","Holder Dong Seon Kim releases all claims under the old note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131262,"accession_number":"0001213900-25-123836","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Ian Zwicker resigns from Emmaus Life Sciences board, effective Dec. 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Zwicker resigned as director of Emmaus Life Sciences, effective December 31, 2025.","Resignation announced on December 15, 2025; filed on December 19, 2025.","No reason for resignation was disclosed; no successor has been named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131261,"accession_number":"0001213900-25-110878","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.","Revenue fell 38% to $3.4M from $5.5M; decline driven by generic L-Glutamine in U.S. and lower MENA sales.","Operating expenses reduced 43% to $2.4M due to workforce reduction and cost cuts.","Income from operations $0.7M vs $0.8M prior year, partially offsetting revenue drop.","Cash and equivalents dropped to $0.3M at Sept 30 from $1.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":8601000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147839,"accession_number":"0001213900-25-076672","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.","Loss from operations $0.4M vs income of $0.6M in prior year.","Net loss $1.1M ($0.02/share) vs $2.2M ($0.03/share) in Q2 2024; decrease due to lower other expense.","Cash balance $0.9M at June 30, 2025, down from $1.4M at year-end 2024.","Operating expenses reduced 33% to $3.0M, primarily from headcount reduction in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":5223000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147838,"accession_number":"0001213900-25-060349","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus CFO Yasushi Nagasaki resigns effective June 30, 2025; Hiroko Huynh promoted to CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yasushi Nagasaki resigned as CFO, effective June 30, 2025, transitioning to full retirement.","Hiroko Huynh promoted to Chief Accounting Officer effective July 1, 2025.","Ms. Huynh, previously Controller since Jan 2020, joined Emmaus in Oct 2018 from Deloitte & Touche LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166557,"accession_number":"0001213900-25-044286","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q1 2025 net loss narrows to $2.3M; revenue flat at $2.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.3M ($0.04/sh) improved from $4.3M loss YoY; operating loss narrowed to $1.0M.","Net revenue $2.4M, down slightly from $2.5M YoY due to generic L-Glutamine competition.","Total operating expenses fell to $3.2M from $5.0M, mainly from workforce reduction in Q4 2024.","Cash and equivalents $1.3M at March 31, 2025, comparable to $1.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2406000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166556,"accession_number":"0001213900-25-039783","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Emmaus Life Sciences replaces auditor Marcum with CBIZ CPAs after acquisition of attest business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor on May 2, 2025, due to CBIZ CPAs acquiring its attest business.","Audit Committee approved engagement of CBIZ CPAs as new independent registered public accounting firm same day.","Marcum's FY2024 audit report contained a going concern emphasis, but no adverse opinion or disclaimer.","No disagreements or reportable events occurred with Marcum during FY2024 or through resignation date.","Emmaus provided Marcum with a copy of this 8-K; Marcum's response letter (Exhibit 16.1) filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166555,"accession_number":"0001213900-25-031624","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.","Loss from operations of $1.9M vs income of $3.5M in 2023.","Net loss $6.5M ($0.10 per share) vs net loss $3.7M ($0.07) in 2023.","Cash at Dec. 31, 2024: $1.4M, down from $2.5M a year earlier.","Management expects 2025 net revenues to reach or exceed 2024 levels."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2406000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200570,"accession_number":"0001213900-24-100231","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.","Q3 income from operations $0.8M (vs $0.02M YoY); net income $1.8M ($0.03 EPS) vs $0.07M.","Nine-month net loss $4.7M ($0.07 per share) vs $4.9M loss in prior year; revenue down 41% due to inventory shortages.","Cash at Sept 30, 2024: $1.3M, down from $2.5M at Dec 31, 2023.","CEO expects full-year results materially lower than 2023; generic competition may affect future Endari sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":13361000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200569,"accession_number":"0001213900-24-094976","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Seah Lim resigns from Emmaus Life Sciences board for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Seah Lim resigned as director on November 4, 2024, citing personal reasons.","No replacement or successor director has been named at this time.","The company expressed gratitude for Dr. Lim's service and support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200568,"accession_number":"0001213900-24-090765","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Emmaus Life Sciences engages Marcum LLP as new auditor for FY 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee appointed Marcum LLP as independent accountant on October 22, 2024.","Marcum will audit the quarter ended September 30, 2024 and year ending December 31, 2024.","Company did not consult Marcum on any matters described in Item 304(a)(2) of Reg S-K prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200567,"accession_number":"0001213900-24-085641","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences board changes: George Sekulich resigns, Jon Kuwahara appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Sekulich resigned from board on Sep 30, 2024, after his termination as Chief Commercial Officer on Oct 4.","Jon Kuwahara appointed to fill vacancy effective Oct 1, 2024; also named Chair of Audit Committee.","Kuwahara served as Emmaus director from Jan 2016 to Sep 2018; now VP-Finance at Crinetics Pharmaceuticals (CRNX).","No family relationships or transactions requiring disclosure under Item 404(a) exist.","Kuwahara is a CPA with a BBA from University of Hawaii; prior roles at Novus Therapeutics and other life sciences firms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216576,"accession_number":"0001213900-24-077411","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["2.02","4.01","9.01"],"status":"ready","headline":"Revenue falls 55% to $7.9M, net loss $6.5M; auditor Baker Tilly declines reappointment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue for H1 2024 was $7.9M, down 55% from $17.5M in H1 2023, due to inventory shortages.","Net loss of $6.5M ($0.10/sh) vs $5.0M ($0.10/sh) in prior year; operating loss $2.2M vs income $2.2M.","Cash at June 30, 2024: $1.5M, down from $2.5M at Dec 31, 2023.","CEO says full-year revenue unlikely to match 2023; generic L-Glutamine launch poses risk to Endari.","Auditor Baker Tilly notified Sept 5, 2024 it will not stand for reappointment; no disagreements but prior reports include going concern note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216575,"accession_number":"0001213900-24-062226","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences appoints Willis Lee as CEO, eliminates interim Co-President role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Willis Lee appointed CEO effective July 15, 2024; previously interim Co-President and COO.","Lee continues as Chairman of the Board (since Oct 2023); compensation unchanged.","George Sekulich, former interim Co-President, continues as Chief Commercial and Information Officer.","Move eliminates the interim Co-President structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216574,"accession_number":"0001213900-24-058821","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.","Net loss $3.7M ($0.07/sh) vs $10.6M ($0.21/sh); cash $2.5M at Dec 31, 2023.","MENA region and U.S. sales drove growth; disposed of Japanese JV equity interest.","Inventory shortage impacted Q4 2023 sales; backlog ~$4.6M as of May 24, 2024; now resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":7883000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236240,"accession_number":"0001213900-24-047151","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Emmaus Life Sciences amends bylaws to establish exclusive forum for stockholder litigation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Amendment to Amended and Restated By-Laws on May 23, 2024.","Delaware Chancery Court designated as sole forum for derivative and internal affairs actions.","Federal district courts designated as exclusive forum for Securities Act claims.","Amendment effective immediately; shareholders deemed to have consented.","Exclusive forum provisions apply to actions based on duties, DGCL, and internal affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}